<DOC>
	<DOC>NCT00754104</DOC>
	<brief_summary>Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors</brief_summary>
	<brief_title>Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Subject must have a histologically or cytologically confirmed nonhematologic malignancy. Subject must have an ECOG Score of 02. Adequate organ function. Subject has received targeted VEGF/PDGF therapy (tyrosine kinase inhibitor) therapy. Prior Avastin allowed. Subject has untreated brain or meningeal metastases. History of greater than 10% weight loss. Has clinically relevant hemoptysis. Subject has proteinuria CTC grade &gt; 1. Must not have had radiation therapy or major surgery within 21 days of study day 1. The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (DBP) &gt; 100 mmHg or systolic blood pressure (SBP) &gt; 150 mmHg. Subjects may be rescreened if blood pressure is shown to be controlled with or without intervention. The subject has a documented left ventricular ejection fraction (LVEF) &lt; 50%.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>